Table 2 Clinicopathological features of patients with AITL developing renal involvement
Author | Sex | Age | Type of renal lesion | Interval (months) | Treatment | Clinical outcome |
|---|---|---|---|---|---|---|
Wood and Harkins [13] | M | 76 | Diffuse proliferative glomerulonephritis | 0 | Corticosteroid, cyclophosphamide | Dead for lymphoma |
Wood and Harkins [13] | M | 79 | Minimal change disease | 0 | Dialysis | Dead for renal failure |
Bhat et al [8] | F | 77 | Acute renal failure with Bence-Jones proteinuria | 4 | None | Dead for sepsis |
Platzer et al [11] | M | 64 | Renal failure | 0 | Prednisolone | CR |
Bello et al [15] | M | 61 | Fanconi syndrome | 0 | Hydrocortisone | CR |
Bignon et al [23] | M | 70 | Dysproteinaemia | 0 | n.a. | n.a. |
Yamazaki et al [26] | M | 72 | Endocapillary proliferative glomerulonephritis | 0 | Vincristine, prednisolone | Dead for alimentary tract bleeding |
Nakamoto et al [10] | M | 40 | Acute interstitial nephritis | 16 | Prednisolone, cyclophosphamide | At 60-month follow-up, no signs of relapse |
Duwaji et al [28] | M | 71 | Proliferative glomerulonephritis | 2 | CHOP regimen | Dead for sepsis |
Lim et al [33] | M | 33 | Amyloidosis | 12 | CHOP regimen | At 12-month follow-up, no signs of relapse |
Hamidou et al [12] | M | 56 | Vasculitis | 0 | CHOP regimen | Dead for renal failure |
De Samblanx et al [2] | M | 67 | Proliferative glomerulonephritis | 0 | CHOP regimen | At 12-month follow-up, no signs of relapse |
Goto et al [9] | M | 73 | Direct invasion by lymphoma | 0 | CHOP regimen | At 20-month follow-up, no signs of relapse |
Miura et al [7] | M | 70 | IgM-λ glomerular thrombi | 2 | CHOP regimen | At 3-month follow-up, no signs of relapse |
Tagashi et al [16] | M | 21 | Nephrotic syndrome | 0 | CHOP regimen | At 36-month follow-up, no signs of relapse |